Danaher Corporation

$214.90
(as of Feb 4, 3:59 PM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

Ticker Information for Danaher Corporation

Stock Price
$214.90
Ticker Symbol
DHR
Exchange
NYSE

Industry Information for Danaher Corporation

Sector
Healthcare
Industry
Diagnostics & Research

Company Description for Danaher Corporation

Country
USA
Full Time Employees
61,000

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies and reagents, and particle counting and characterization; microscopes; protein consumables; industrial filtration products; and genomic medicines, such as custom nucleic acid products, plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX and SCIEX brands. The Diagnostics segment offers chemistry, immunoassay, microbiology, and automation systems; and molecular, acute care, and pathology diagnostics products. This segment also provides clinical instruments, reagents, consumables, software, and services for hospitals, physicians' offices, reference laboratories, and other critical care settings. The company has a research collaboration with Stanford University's Department of Bioengineering for cancer drug development. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and is based in Washington, the District of Columbia.

Fundamentals for Danaher Corporation

Market Capitalization
$154,613,694,464
EBITDA
$7,511,000,064
Dividends per Share
$0
P/E Ratio
40.49
Forward P/E Ratio
28.17
Earnings per Share
$5.31
Earnings per Share Estimate Next Year
$8.65
Profit Margin
16.39%
Shares Outstanding
719,100,032
Percent Owned by Insiders
11.00%
Percent Owned by Institutions
81.57%
52-Week High
$281.10
52-Week Low
$210.04

Technical Indicators for Danaher Corporation

50-Day Moving Average
$234.88
200-Day Moving Average
$253.14
RSI
30.06
6.77

Analyst Ratings for Danaher Corporation

Strong Buy
18
Buy
5
Hold
5
Sell
0
Strong Sell
0

News About Danaher Corporation

Feb 3, 2025, 12:47 PM EST
We recently published a list of the 10 Best Cancer Stocks to Buy According to Hedge Funds. See more.
Feb 3, 2025, 11:33 AM EST
Investing.com -- Raymond James downgraded Danaher Corporation (NYSE:DHR) to "Market Perform" from "Outperform," citing concerns over the company's growth trajectory following its fourth-quarter results and guidance that lagged peers. See more.
Feb 1, 2025, 3:44 AM EST
We recently compiled a list of the 12 Best Long Term Low Risk Stocks to Buy Right Now.In this article, we are going to take a look at where Danaher Corporation (NYSE:DHR) stands against the other long term low risk stocks. See more.
Jan 31, 2025, 4:47 PM EST
We recently published an article titled Jim Cramer Discusses These 10 Stocks & Says He's In Waiting For AI GPU Spending Clarity.In this article, we are going to take a look at where Danaher Corporation (NYSE:DHR) stands against the other stocks Jim Cramer recently discussed. See more.
Jan 31, 2025, 1:11 PM EST
Danaher’s (NYSE:DHR) Q4 Sales Beat Estimates See more.